Abstract
Chromatin remodeler ARID1A regulates gene transcription by modulating nucleosome positioning and chromatin accessibility. While ARID1A-mediated stage and lineage-restricted gene regulation during cell fate canalization remains unresolved. Using osteoclastogenesis as a model, we show that ARID1A transcriptionally safeguards the osteoclast (OC) fate canalization during proliferation-differentiation switching at single-cell resolution. Notably, ARID1A is indispensable for the transcriptional apparatus condensates formation with coactivator BRD4/lineage-specifying transcription factor (TF) PU.1 at Nfatc1 super-enhancer during safeguarding the OC fate canalization. Besides, the antagonist function between ARID1A-cBAF and BRD9-ncBAF complex during osteoclastogenesis has been validated with in vitro assay and compound mutant mouse model. Furthermore, the antagonistic function of ARID1A-"accelerator" and BRD9-"brake" both depend on coactivator BRD4-"clutch" during osteoclastogenesis. Overall, these results uncover sophisticated cooperation between chromatin remodeler ARID1A, coactivator, and lineage-specifying TF at super-enhancer of lineage master TF in a condensate manner, and antagonist between distinct BAF complexes in the proper and balanced cell fate canalization.
Introduction
In the skeletal system, bone health depends on a delicate balance between bone-forming osteoblasts and bone-resorbing osteoclasts. The process of creating an osteoclast (osteoclastogenesis) requires a myeloid progenitor cell to commit to a specific identity through a process called canalization. While transcription factors and chromatin remodelers like the BAF complex are known players, the precise mechanisms governing the switch from proliferation to differentiation have remained elusive. This study identifies ARID1A, a core component of the canonical BAF (cBAF) complex, as the essential safeguard for this high-stakes cell fate decision.
Methods
The researchers employed a multi-omic approach to track cell fate at high resolution. They generated myeloid-specific ARID1A knockout mice (LysM-Cre; Arid1a^fl/fl) to study the effects in vivo. Using scRNA-seq, they mapped the differentiation trajectory of over 11,000 cells, identifying the exact stage where differentiation stalls. This was complemented by ChIP-seq to locate binding sites for ARID1A, the coactivator BRD4, and the transcription factor PU.1, and 3C-qPCR to measure physical chromatin looping between the Nfatc1 super-enhancer and its promoter.
Results
ARID1A Deficiency Leads to Increased Bone Mass
Mice lacking ARID1A in myeloid cells developed a striking osteopetrosis-like phenotype. Micro-CT analysis of long bones revealed a significant increase in trabecular bone density, as the cells failed to produce enough functional osteoclasts to maintain normal bone resorption.
Quantitative morphometric analysis confirmed these visual findings. Mutant mice showed significantly higher bone volume fraction (BV/TV), bone mineral density (BMD), and trabecular number (Tb.N), alongside a decrease in trabecular spacing (Tb.Sp).
The Molecular Mechanism: A Transcriptional "Accelerator"
At the molecular level, ARID1A acts as a safeguard for the proliferation-to-differentiation switch. It specifically targets the super-enhancer of Nfatc1, the master regulator of osteoclast identity. The study provides evidence that ARID1A, BRD4, and PU.1 form physical phase-separated condensates—liquid-like droplets that concentrate the transcriptional machinery at the Nfatc1 locus.
In the absence of ARID1A, these condensates fail to form properly, recruitment of the coactivator BRD4 is compromised, and the physical looping required to activate Nfatc1 expression is lost. This leads to a significant down-regulation of key osteoclast genes such as Ctsk, Mmp9, and Acp5.
Discussion
The authors propose a mechanical analogy for gene regulation during osteoclastogenesis:
- ARID1A (cBAF): The "Accelerator" that drives differentiation.
- BRD9 (ncBAF): The "Brake" that restrains the process.
- BRD4: The "Clutch" that both complexes depend on to engage with the genome.
This antagonistic relationship ensures a balanced cell fate canalization. While the bone mass increase was prominent in trabecular bone, the lack of significant change in cortical bone suggests potential redundant regulatory mechanisms in different skeletal compartments. These findings open new avenues for treating bone-wasting diseases like osteoporosis by potentially targeting these super-enhancer condensates to modulate bone resorption.
Summary updated